MLchartDataset catalogue

CT-2103

Term · Oncology and biomedicine · MLC-T-ONC-002163

A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called paclitaxel poliglumex, paclitaxel polyglutamate, and Xyotax.

Table 1. Record
IdentifierMLC-T-ONC-002163
FieldOncology and biomedicine
Expansionspaclitaxel poliglumex; paclitaxel polyglutamate; Xyotax
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-002163",
  "term": "CT-2103",
  "field": "Oncology and biomedicine",
  "definition": "A form of the anticancer drug paclitaxel combined with a protein called poliglumex that may have fewer side effects and work better than paclitaxel. It is being studied in the treatment of breast cancer, ovarian cancer, lung cancer, and other types of cancer. It belongs to the family of drugs called mitotic inhibitors. Also called paclitaxel poliglumex, paclitaxel polyglutamate, and Xyotax.",
  "expansions": [
    "paclitaxel poliglumex",
    "paclitaxel polyglutamate",
    "Xyotax"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/ct-2103/"
}

Record 5,477 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.